Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
207
NCT00322608
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 30, 2006
Completion: Dec 31, 2009
NCT00630110
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase 1/2
Start: Feb 29, 2008
Completion: Jun 30, 2011